Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 40 studies | 63% ± 27% | |
pericyte | 24 studies | 41% ± 15% | |
smooth muscle cell | 21 studies | 43% ± 19% | |
connective tissue cell | 14 studies | 57% ± 23% | |
mesothelial cell | 12 studies | 60% ± 23% | |
myofibroblast cell | 12 studies | 58% ± 24% | |
endothelial cell of lymphatic vessel | 10 studies | 30% ± 7% | |
epithelial cell | 10 studies | 32% ± 17% | |
ciliated cell | 8 studies | 25% ± 8% | |
glial cell | 6 studies | 42% ± 23% | |
ionocyte | 5 studies | 76% ± 14% | |
renal alpha-intercalated cell | 5 studies | 39% ± 12% | |
abnormal cell | 5 studies | 41% ± 23% | |
intestinal crypt stem cell | 5 studies | 33% ± 14% | |
transit amplifying cell | 5 studies | 27% ± 8% | |
hepatocyte | 5 studies | 58% ± 32% | |
epithelial cell of proximal tubule | 4 studies | 29% ± 18% | |
astrocyte | 4 studies | 45% ± 19% | |
retinal pigment epithelial cell | 4 studies | 37% ± 20% | |
endothelial cell | 4 studies | 28% ± 5% | |
adventitial cell | 4 studies | 63% ± 19% | |
Mueller cell | 4 studies | 58% ± 24% | |
oligodendrocyte precursor cell | 4 studies | 27% ± 8% | |
basal cell | 4 studies | 19% ± 1% | |
secretory cell | 4 studies | 24% ± 4% | |
type I pneumocyte | 3 studies | 31% ± 11% | |
renal beta-intercalated cell | 3 studies | 68% ± 24% | |
neural crest cell | 3 studies | 43% ± 8% | |
kidney distal convoluted tubule epithelial cell | 3 studies | 56% ± 12% | |
kidney loop of Henle epithelial cell | 3 studies | 28% ± 10% | |
goblet cell | 3 studies | 23% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 30681.18 | 226 / 226 | 99% | 1102.61 | 400 / 406 |
pancreas | 100% | 11337.69 | 328 / 328 | 93% | 219.13 | 166 / 178 |
kidney | 100% | 7267.39 | 89 / 89 | 93% | 390.41 | 837 / 901 |
ovary | 100% | 18623.13 | 180 / 180 | 89% | 181.44 | 384 / 430 |
lung | 100% | 13413.60 | 577 / 578 | 82% | 112.34 | 950 / 1155 |
breast | 100% | 8818.23 | 457 / 459 | 70% | 74.95 | 780 / 1118 |
prostate | 99% | 8564.80 | 243 / 245 | 69% | 64.83 | 345 / 502 |
intestine | 99% | 8881.76 | 954 / 966 | 69% | 71.04 | 362 / 527 |
bladder | 100% | 8250.33 | 21 / 21 | 63% | 90.54 | 315 / 504 |
uterus | 99% | 14493.15 | 169 / 170 | 61% | 96.74 | 279 / 459 |
stomach | 81% | 4358.64 | 292 / 359 | 70% | 71.44 | 199 / 286 |
adrenal gland | 100% | 70189.08 | 258 / 258 | 50% | 363.11 | 116 / 230 |
thymus | 87% | 2627.96 | 565 / 653 | 44% | 47.31 | 268 / 605 |
esophagus | 81% | 5890.87 | 1175 / 1445 | 37% | 28.43 | 68 / 183 |
adipose | 100% | 9619.01 | 1204 / 1204 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 103.47 | 1 / 1 |
blood vessel | 98% | 5347.96 | 1303 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 160.56 | 28 / 29 |
spleen | 95% | 4648.26 | 229 / 241 | 0% | 0 | 0 / 0 |
skin | 43% | 1497.58 | 776 / 1809 | 43% | 38.94 | 201 / 472 |
eye | 0% | 0 | 0 / 0 | 73% | 90.27 | 58 / 80 |
brain | 35% | 799.90 | 931 / 2642 | 27% | 40.82 | 187 / 705 |
heart | 50% | 2338.66 | 432 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 40% | 42.06 | 18 / 45 |
muscle | 2% | 46.97 | 18 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 14.06 | 4 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0061760 | Biological process | antifungal innate immune response |
GO_0006954 | Biological process | inflammatory response |
GO_0050921 | Biological process | positive regulation of chemotaxis |
GO_0045087 | Biological process | innate immune response |
GO_0050829 | Biological process | defense response to Gram-negative bacterium |
GO_0048566 | Biological process | embryonic digestive tract development |
GO_0006935 | Biological process | chemotaxis |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0010759 | Biological process | positive regulation of macrophage chemotaxis |
GO_0001523 | Biological process | retinoid metabolic process |
GO_0008286 | Biological process | insulin receptor signaling pathway |
GO_0050830 | Biological process | defense response to Gram-positive bacterium |
GO_0050994 | Biological process | regulation of lipid catabolic process |
GO_0030154 | Biological process | cell differentiation |
GO_0045600 | Biological process | positive regulation of fat cell differentiation |
GO_0019732 | Biological process | antifungal humoral response |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0031012 | Cellular component | extracellular matrix |
GO_0031089 | Cellular component | platelet dense granule lumen |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | RARRES2 |
Protein name | Retinoic acid receptor responder protein 2 (Chemerin) Retinoic acid receptor responder protein 2 (Chemerin) (RAR-responsive protein TIG2) (Tazarotene-induced gene 2 protein) |
Synonyms | TIG2 tcag7.770 |
Description | FUNCTION: Adipocyte-secreted protein (adipokine) that regulates adipogenesis, metabolism and inflammation through activation of the chemokine-like receptor 1 (CMKLR1). Acts also as a ligand for CMKLR2. Can also bind to C-C chemokine receptor-like 2 (CCRL2), but with a lower affinity than it does to CMKLR1 or CMKLR2 . Positively regulates adipocyte differentiation, modulates the expression of adipocyte genes involved in lipid and glucose metabolism and might play a role in angiogenesis, a process essential for the expansion of white adipose tissue. Also acts as a pro-inflammatory adipokine, causing an increase in secretion of pro-inflammatory and prodiabetic adipokines, which further impair adipose tissue metabolic function and have negative systemic effects including impaired insulin sensitivity, altered glucose and lipid metabolism, and a decrease in vascular function in other tissues. Can have both pro- and anti-inflammatory properties depending on the modality of enzymatic cleavage by different classes of proteases. Acts as a chemotactic factor for leukocyte populations expressing CMKLR1, particularly immature plasmacytoid dendritic cells, but also immature myeloid DCs, macrophages and natural killer cells. Exerts an anti-inflammatory role by preventing TNF/TNFA-induced VCAM1 expression and monocytes adhesion in vascular endothelial cells. The effect is mediated via inhibiting activation of NF-kappa-B and CRK/p38 through stimulation of AKT1/NOS3 signaling and nitric oxide production. Its dual role in inflammation and metabolism might provide a link between chronic inflammation and obesity, as well as obesity-related disorders such as type 2 diabetes and cardiovascular disease. Exhibits an antimicrobial function in the skin. . |
Accessions | A0A090N7U9 Q99969 ENST00000482669.1 ENST00000223271.8 ENST00000467793.5 C9J8S2 ENST00000466675.5 |